As FDA Focuses on Safety, Fewer New Drugs Are Approved - Wall Street Journal (Vioxx News)
For one, there’s the industry’s research labs, which have produced a leaky pipeline of promising products lately. Janet Woodcock, head of the FDA’s Center for Drug Evaluation and Research, notes that new drug applications submitted to the FDA Read More
Nearly four years after Merck & Co. yanked the painkiller Vioxx off the market, beleaguered pharmaceutical-industry executives say they are facing a tough new regulatory climate that is altering the landscape of drug development. Over the past 16 Read More
